181 related articles for article (PubMed ID: 2844304)
1. HT 29, a model cell line: stimulation by the vasoactive intestinal peptide (VIP); VIP receptor structure and metabolism.
Marchis-Mouren G; Martin JM; Luis J; el Battari A; Muller JM; Marvaldi J; Pichon J
Biochimie; 1988 May; 70(5):663-71. PubMed ID: 2844304
[TBL] [Abstract][Full Text] [Related]
2. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
Couvineau A; Rousset M; Laburthe M
Biochem J; 1985 Oct; 231(1):139-43. PubMed ID: 2998337
[TBL] [Abstract][Full Text] [Related]
3. Covalent cross-linking of vasoactive intestinal peptide (VIP) to its receptor in intact colonic adenocarcinoma cells in culture (HT 29).
Muller JM; Luis J; Fantini J; Abadie B; Giannellini F; Marvaldi J; Pichon J
Eur J Biochem; 1985 Sep; 151(2):411-7. PubMed ID: 2992966
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
Gespach C; Bawab W; de Cremoux P; Calvo F
Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
[TBL] [Abstract][Full Text] [Related]
6. Characterization of receptors for VIP on pancreatic acinar cell plasma membranes using covalent cross-linking.
McArthur KE; Wood CL; O'Dorisio MS; Zhou ZC; Gardner JD; Jensen RT
Am J Physiol; 1987 Mar; 252(3 Pt 1):G404-12. PubMed ID: 2435170
[TBL] [Abstract][Full Text] [Related]
7. A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29.
Turner JT; Jones SB; Bylund DB
Peptides; 1986; 7(5):849-54. PubMed ID: 3025826
[TBL] [Abstract][Full Text] [Related]
8. Parallel activation of cyclic AMP phosphodiesterase and cyclic AMP-dependent protein kinase in two human gut adenocarcinoma cells (HT 29 and HRT 18) in culture, by vasoactive intestinal peptide (VIP) and other effectors activating the cyclic AMP system.
Mangeat P; Marvaldi J; Ahmed OA; Marchis-Mouren G
Regul Pept; 1981 Mar; 1(6):397-414. PubMed ID: 6262879
[TBL] [Abstract][Full Text] [Related]
9. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
10. Covalent cross-linking of vasoactive intestinal polypeptide to its receptors on intact human lymphoblasts.
Wood CL; O'Dorisio MS
J Biol Chem; 1985 Jan; 260(2):1243-7. PubMed ID: 2981838
[TBL] [Abstract][Full Text] [Related]
11. Selective photolabeling of high and low affinity binding sites for vasoactive intestinal peptide (VIP): evidence for two classes of covalent VIP-receptor complexes in intestinal cell membranes.
Robichon A; Marie JC
Endocrinology; 1987 Mar; 120(3):978-85. PubMed ID: 3026793
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.
Salomon R; Couvineau A; Rouyer-Fessard C; Voisin T; Lavallée D; Blais A; Darmoul D; Laburthe M
Am J Physiol; 1993 Feb; 264(2 Pt 1):E294-300. PubMed ID: 8383439
[TBL] [Abstract][Full Text] [Related]
13. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells.
el Battari A; Martin JM; Luis J; Pouzol O; Secchi J; Marvaldi J; Pichon J
J Biol Chem; 1988 Nov; 263(33):17685-9. PubMed ID: 2846575
[TBL] [Abstract][Full Text] [Related]
14. Cyclic AMP-dependent protein kinase in Molt 4b lymphoblasts: identification by photoaffinity labeling and activation in intact cells by vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI).
O'Dorisio MS; Wood CL; Wenger GD; Vassalo LM
J Immunol; 1985 Jun; 134(6):4078-86. PubMed ID: 2985703
[TBL] [Abstract][Full Text] [Related]
15. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
[TBL] [Abstract][Full Text] [Related]
16. Combined ultrastructural and biochemical study of cellular processing of vasoactive intestinal peptide and its receptors in human colonic carcinoma cells in culture.
Hejblum G; Gali P; Boissard C; Astesano A; Marie JC; Anteunis A; Hui Bon Hoa D; Rosselin G
Cancer Res; 1988 Nov; 48(21):6201-10. PubMed ID: 2844402
[TBL] [Abstract][Full Text] [Related]
17. The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor.
Couvineau A; Laburthe M
Biochem J; 1985 Jan; 225(2):473-9. PubMed ID: 3977841
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
19. VIP receptors and control of short circuit current in the human intestinal clonal cell line Cl.19A.
Rouyer-Fessard C; Augeron C; Grasset E; Maoret JJ; Laboisse CL; Laburthe M
Experientia; 1989 Dec; 45(11-12):1102-5. PubMed ID: 2557231
[TBL] [Abstract][Full Text] [Related]
20. Development of vasoactive intestinal peptide-responsive adenylate cyclase during enterocytic differentiation of Caco-2 cells in culture. Evidence for an increased receptor level.
Laburthe M; Rousset M; Rouyer-Fessard C; Couvineau A; Chantret I; Chevalier G; Zweibaum A
J Biol Chem; 1987 Jul; 262(21):10180-4. PubMed ID: 3038870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
